Onyx Pharmaceuticals Inc. (ONXX: Quote) announced after the bell Wednesday that the FDA's Oncologic Drugs Advisory Committee determined by a vote of 11-0 that, in patients with relapsed and refractory multiple myeloma who have received at least two prior lines of therapy that included a proteasome inhibitor and an immunomodulatory agent, the benefit-risk assessment is favorable for the use of Kyprolis.
Onyx Pharmaceuticals has gapped open dramatically higher Wedneday and is now up 17.50 at $62.08 on strong volume. The stock has surged to a new high for the year.
Click here to receive FREE breaking news email alerts for Onyx Pharmaceuticals Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org